Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.

1994 ◽  
Vol 1 (6) ◽  
pp. 670-677 ◽  
Author(s):  
C Osiowy ◽  
D Horne ◽  
R Anderson
Keyword(s):  
Respiratory Syncytial Virus ◽  
Virus Infection ◽  
Respiratory Syncytial Virus Infection ◽  
Antibody Dependent Enhancement ◽  
Young Infants ◽  
Syncytial Virus

Ribavirin Use Questioned

PEDIATRICS ◽  
1988 ◽  
Vol 82 (2) ◽  
pp. 283-284
Author(s):  
JULIA A. MCMILLAN ◽  
LEONARD B. WEINER
Keyword(s):  
Respiratory Syncytial Virus ◽  
Virus Infection ◽  
Respiratory Syncytial Virus Infection ◽  
Critical Review ◽  
Young Infants ◽  
Fda Approval ◽  
Syncytial Virus

In Reply.— The concerns of Dashefsky et al regarding the validity of the studies that led to the FDA approval of aerosolized ribavirin for the treatment of patients with respiratory syncytial virus infection are well described in their critical review of those studies.1 We agree that none of those studies provided the kind of conclusive quantification of ribavirin's efficacy that should preclude further placebocontrolled trials. Nonetheless, ribavirin is on the market, and physicians who care for young infants hospitalized with respiratory syncytial virus infection must decide whether and when it should be used.

Sign in / Sign up

Export Citation Format

Share Document